# Early Management Strategies of Acute Heart Failure for Patients With NSTEMI

Study · id `cardio:ct-nct03189901` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03189901](<https://clinicaltrials.gov/study/NCT03189901>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03189901

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 470 participants.

## Technical summary

Registry record NCT03189901. Randomized; no masking; primary purpose treatment. Start 2017-07-01 (actual); primary completion 2021-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 470 participants (planned count; ClinicalTrials.gov record NCT03189901, source copy `cardio:ctgov-nct03189901-2021-07-19`, retrieved 2026-10-26)
- Started: 2017-07-01 (actual) (ClinicalTrials.gov record NCT03189901, source copy `cardio:ctgov-nct03189901-2021-07-19`, retrieved 2026-10-26)
- Primary completion: 2021-12-31 (anticipated) (ClinicalTrials.gov record NCT03189901, source copy `cardio:ctgov-nct03189901-2021-07-19`, retrieved 2026-10-26)
- Completion: 2021-12-31 (anticipated) (ClinicalTrials.gov record NCT03189901, source copy `cardio:ctgov-nct03189901-2021-07-19`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT03189901, source copy `cardio:ctgov-nct03189901-2021-07-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03189901-2021-07-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: Early Management Strategies of Acute Heart Failure for Patients With NSTEMI
- Acronym: EMSAHF
- Condition: Early Management
- Condition: Acute Heart Failure
- Condition: NSTEMI - Non-ST Segment Elevation MI
- Intervention (Drug): Regular management+Levosimendan
- Lead sponsor: Qilu Hospital of Shandong University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: Non-ST-elevation heart attack (NSTEMI) (`cardio:nstemi`)
- Registry lists this organization as the lead sponsor: Qilu Hospital of Shandong University (`cardio:org-qilu-hospital-of-shandong-university`)

## Provenance

Content hash: 7689459863635e883b68907e81e94b32b9828740a40e485c4b88e6c5aac1248e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
